Arcutis Biotherapeutics
D

ARQT

31.190
USD
-1.00
(-3.11%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
56,653
الربح لكل سهم
-2
العائد الربحي
-
P/E
142
حجم السوق
3,920,332,264
نظرة عامة
أصول ذات صلة
ABBV
ABBV
D
شركة أب في
285.67
0.71(0.25%)
286.00+0.33(+0.12%)
AZN
AZN
D
أسترازينيكا
171.490
-1.090(-0.63%)
BNTX
BNTX
D
BioNTech SE American Depositary Share
88.080
-1.590(-1.77%)
GSK
GSK
D
GSK plc
50.750
-0.460(-0.90%)
JNJ
JNJ
D
جونسون آند جونسون
263.86
-3.84(-1.43%)
263.09-0.77(-0.29%)
MRK
MRK
D
ميرك اند كو
145.270
-1.970(-1.34%)
145.280+0.010(+0.01%)
MRNA
MRNA
D
Moderna
200.090
-2.540(-1.25%)
201.280+1.190(+0.59%)
NVAX
D
Novavax
9.69500
-0.29000(-2.90%)
9.74000+0.04500(+0.46%)
PFE
PFE
D
فايزر
30.015
-0.400(-1.32%)
30.020+0.005(+0.02%)
المزيد

العنوان: Arcutis Biotherapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.